# Personalis Agrees to $1.5B Acquisition by Tempus AI to Integrate MRD Oncology Testing

> ma · REPORTED · 2026-07-20

Personalis announced it has entered into a definitive agreement to be acquired by Tempus AI at $16.25 per share, representing a total enterprise value of approximately $1.5 billion; the deal adds Personalis's ultrasensitive NeXT Personal tumor-informed MRD test, with Medicare coverage in three cancer indications, to Tempus's platform.

About Personalis: Personalis is a cancer-focused genomics company specializing in advanced genomic sequencing and minimal residual disease testing, offering the NeXT Personal MRD test for monitoring cancer treatment response and recurrence.

- Company: Personalis
- Sector: oncology
- Primary source: https://srnnews.com/tempus-to-acquire-personalis-for-1-5-billion/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.